← Leaderboards
Betty Diamond
Feinstein Institute For Medical Research
$68,537,262
Attributed
$77,727,995
Total exposure
44
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$148,409,142 · 50
By mechanism
P01$81,524,995 · 21
U19$25,803,789 · 7
R01$15,861,430 · 9
UH2$9,031,114 · 1
T32$5,269,431 · 1
UG3$3,360,533 · 1
Top collaborators
- Anne Davidson12 shared
- David Wofsy11 shared
- Sun Jung Kim5 shared
- Kevin J. Tracey5 shared
- Peter K. Gregersen4 shared
Most similar at Feinstein Institute For Medical Research
Same institution · by research overlap
- Anne Davidson$18,272,977
- Patricio T Huerta$8,195,375
- Bruce Thomas Volpe$13,363,924
- Venkatesh Jeganathan$78,505
- Weiqing Huang$162,516
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
- Judith A James · Oklahoma Medical Research Foundation$25,928,644
Research focus
Systemic Lupus ErythematosusLupusCellsBrainAntibodiesProgramsResearch PersonnelDiamondN-Methyl-D-Aspartate ReceptorsB-LymphocytesClinical TrialsLeadSerumProductionMediatingImmunePathogenicityPathway InteractionsTissuesAnti-Dna AntibodiesAntigensNeuronsExhibitsInflammatory
Grant awards (200)
Learning from Remission and Relapse in SLE$2,678,601
P01 · FY2025 · AI · contact PI
Anti-NMDA Receptor Antibodies in Adult Brain Dysfunction: Lessons from Lupus$2,506,124
P01 · FY2025 · AI · contact PI
Antibody-triggered mouse models of neuropsychiatric lupus: heterogeneity, mechanisms and therapeutic approaches$1,203,592
P01 · FY2025 · AI · contact PI
A mechanistic understanding of B cell and macrophage plasticity in lupus disease activity states$779,404
U19 · FY2025 · AI · contact PI
Origin and function of atypical lymphocyte populations in inflamed tissue in SLE and RA$721,185
P01 · FY2025 · AI · contact PI
Acquisition of high-parameter fluorescent-activated cell sorter analyzer$689,031
S10 · FY2025 · OD · contact PI
Principal Project-Characterization of ANA+ and ANA-B cells in individuals with SLE and healthy subjects$335,000
U19 · FY2025 · AI · contact PI
Administrative Core$137,621
P01 · FY2025 · AI · contact PI
Learning from Remission and Relapse in SLE$132,967
P01 · FY2025 · AI · contact PI
Administrative Core - Core A$114,433
P01 · FY2025 · AI · contact PI
Learning from Remission and Relapse in SLE$90,908
P01 · FY2025 · AI · contact PI
Administrative Core$48,689
U19 · FY2025 · AI · contact PI
Learning from Remission and Relapse in SLE$2,902,477
P01 · FY2024 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$2,858,960
P01 · FY2024 · AI · contact PI
A mechanistic understanding of B cell and macrophage plasticity in lupus disease activity states$794,260
U19 · FY2024 · AI · contact PI
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain$709,832
P01 · FY2024 · AI · contact PI
Origin and function of atypical lymphocyte populations in inflamed tissue in SLE and RA$530,786
P01 · FY2024 · AI · contact PI
Principal Project-Characterization of ANA+ and ANA-B cells in individuals with SLE and healthy subjects$251,183
U19 · FY2024 · AI · contact PI
Administrative Core$208,181
U19 · FY2024 · AI · contact PI
Administrative Core$160,770
P01 · FY2024 · AI · contact PI
Core A - Administrative Core$106,416
P01 · FY2024 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$3,039,860
P01 · FY2023 · AI · contact PI
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain$640,922
P01 · FY2023 · AI · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$639,114
U19 · FY2023 · AI · contact PI
Origin and function of atypical lymphocyte populations in inflamed tissue in SLE and RA$626,695
P01 · FY2023 · AI · contact PI
Alteration of function and specificity of TFH in SLE$551,646
R01 · FY2023 · AR · contact PI
Administrative Core$395,108
U19 · FY2023 · AI · contact PI
Project-003$244,006
U19 · FY2023 · AI · contact PI
Core A - Administrative Core$132,174
P01 · FY2023 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$3,160,921
P01 · FY2022 · AI · contact PI
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain$623,313
P01 · FY2022 · AI · contact PI
Alteration of function and specificity of TFH in SLE$547,589
R01 · FY2022 · AR · contact PI
Origin and function of atypical lymphocyte populations in inflamed tissue in SLE and RA$498,353
P01 · FY2022 · AI · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$316,209
U19 · FY2022 · AI · contact PI
Project-003$221,981
U19 · FY2022 · AI · contact PI
Core A - Administrative Core$143,910
P01 · FY2022 · AI · contact PI
Administrative Core$94,228
U19 · FY2022 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$3,039,165
P01 · FY2021 · AI · contact PI
Etiology and outcome of MIS-C (PRISM)$684,079
U19 · FY2021 · AI · contact PI
Origin and function of atypical lymphocyte populations in inflamed tissue in SLE and RA$622,074
P01 · FY2021 · AI · contact PI
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain$555,651
P01 · FY2021 · AI · contact PI
Alteration of function and specificity of TFH in SLE$539,386
R01 · FY2021 · AR · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$319,827
U19 · FY2021 · AI · contact PI
Project-003$239,913
U19 · FY2021 · AI · contact PI
Effect of Covid-19 engagement of ACE2 on brain health and pathology$196,504
P01 · FY2021 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$189,456
P01 · FY2021 · AI · contact PI
Core A - Administrative Core$138,721
P01 · FY2021 · AI · contact PI
Administrative Core$79,914
U19 · FY2021 · AI · contact PI
Anti NMDA Receptor antibodes in adult brain dysfunction and fetal brain development: lessons from lupus$2,883,980
P01 · FY2020 · AI · contact PI
Etiology and outcome of MIS-C$1,491,907
U19 · FY2020 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$1,063,616
UH2 · FY2020 · AR · contact PI
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain$621,507
P01 · FY2020 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$599,210
UH2 · FY2020 · AR · contact PI
Alteration of function and specificity of TFH in SLE$559,016
R01 · FY2020 · AR · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$469,412
UH2 · FY2020 · AR · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$446,734
U19 · FY2020 · AI · contact PI
Core A - Administrative Core$148,102
P01 · FY2020 · AI · contact PI
Administrative Core$79,501
U19 · FY2020 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$1,300,724
UH2 · FY2019 · AR · contact PI
Alteration of function and specificity of TFH in SLE$595,714
R01 · FY2019 · AR · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$541,250
U19 · FY2019 · AI · contact PI
Administrative Core$81,916
U19 · FY2019 · AI · contact PI
Autoreactive and anti-microbial plasma cell differentiation in SLE$81,914
U19 · FY2019 · AI · contact PI
Anti-NMDA receptor antibodies in adult brain dsyfunction & fetal brain developmen$2,672,219
P01 · FY2018 · AI · contact PI
Cognitive and immune impairments in sepsis survivors$2,292,587
P01 · FY2018 · AI · contact PI
Antibody modulation of neural endocrine networks$883,036
P01 · FY2018 · AI · contact PI
Immune function in sepsis survivors$316,741
P01 · FY2018 · AI · contact PI
Administrative Core$108,500
P01 · FY2018 · AI · contact PI
Administrative Core$43,674
P01 · FY2018 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$2
UH2 · FY2018 · AR · contact PI
Cognitive and immune impairments in sepsis survivors$2,292,587
P01 · FY2017 · AI · contact PI
Anti-NMDA receptor antibodies in adult brain dsyfunction & fetal brain developmen$2,270,547
P01 · FY2017 · AI · contact PI
Prenatal Autoimmune and Inflammatory Risk Factors for Autism Spectrum Disorders$1,846,305
UG3 · FY2017 · OD
PEARL: Pathway Exploration and Analysis in Renal Lupus$825,698
UH2 · FY2017 · AR · contact PI
Antibody modulation of neural endocrine networks$676,930
P01 · FY2017 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$639,491
UH2 · FY2017 · AR · contact PI
Immune function in sepsis survivors$310,926
P01 · FY2017 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$210,606
UH2 · FY2017 · AR · contact PI
Administrative Core$74,703
P01 · FY2017 · AI · contact PI
Administrative Core$45,107
P01 · FY2017 · AI · contact PI
Cognitive and immune impairments in sepsis survivors$2,292,587
P01 · FY2016 · AI · contact PI
Anti-NMDA receptor antibodies in adult brain dsyfunction & fetal brain developmen$2,270,547
P01 · FY2016 · AI · contact PI
Prenatal Autoimmune and Inflammatory Risk Factors for Autism Spectrum Disorders$1,514,228
UG3 · FY2016 · OD
PEARL: Pathway Exploration and Analysis in Renal Lupus$1,122,353
UH2 · FY2016 · AR · contact PI
Antibody modulation of neural endocrine networks$785,445
P01 · FY2016 · AI · contact PI
Immune function in sepsis survivors$312,633
P01 · FY2016 · AI · contact PI
Function of the IRF5 risk allele for SLE in B cells$185,350
R21 · FY2016 · AR · contact PI
Administrative Core$83,515
P01 · FY2016 · AI · contact PI
Administrative Core$43,462
P01 · FY2016 · AI · contact PI
Cognitive and immune impairments in sepsis survivors$2,292,587
P01 · FY2015 · AI · contact PI
Anti-NMDA receptor antibodies in adult brain dsyfunction & fetal brain developmen$2,270,547
P01 · FY2015 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$1,700,001
UH2 · FY2015 · AR · contact PI
Antibody modulation of neural endocrine networks$612,798
P01 · FY2015 · AI · contact PI
Immune function in sepsis survivors$310,926
P01 · FY2015 · AI · contact PI
Function of the IRF5 risk allele for SLE in B cells$222,420
R21 · FY2015 · AR · contact PI
Administrative Core$73,588
P01 · FY2015 · AI · contact PI
Administrative Core$45,107
P01 · FY2015 · AI · contact PI
Cognitive and immune impairments in sepsis survivors$2,292,587
P01 · FY2014 · AI · contact PI
Anti-NMDA receptor antibodies in adult brain dsyfunction & fetal brain developmen$2,287,670
P01 · FY2014 · AI · contact PI
PEARL: Pathway Exploration and Analysis in Renal Lupus$1,100,001
UH2 · FY2014 · AR · contact PI
Antibody modulation of neural endocrine networks$617,419
P01 · FY2014 · AI · contact PI
Toward a new approach to SLE therapy$351,389
R01 · FY2014 · AR · contact PI
Immune function in sepsis survivors$310,926
P01 · FY2014 · AI · contact PI
Nelfinavir in SLE: A Pilot Phase IIa Clinical Trial$168,500
R21 · FY2014 · AR · contact PI
Administrative Core$74,143
P01 · FY2014 · AI · contact PI
Administrative Core$45,107
P01 · FY2014 · AI · contact PI
Toward a new approach to SLE therapy$340,632
R01 · FY2013 · AR · contact PI
Nelfinavir in SLE: A Pilot Phase IIa Clinical Trial$250,644
R21 · FY2013 · AR · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$2,221,830
P01 · FY2012 · AI · contact PI
Toward a new approach to SLE therapy$358,560
R01 · FY2012 · AR · contact PI
Preventing anti-NMDAR Ab neurotoxicity: Rational therapies for NPSLE$318,645
P01 · FY2012 · AI · contact PI
Monoclonal Antibody Core$202,582
P01 · FY2012 · AI · contact PI
Administrative Core$125,649
P01 · FY2012 · AI · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$2,206,554
P01 · FY2011 · AI · contact PI
Toward a new approach to SLE therapy$358,560
R01 · FY2011 · AR · contact PI
Anti-Microbial Antibodies Induce Neuropsychiatric Syndromes$352,953
R01 · FY2011 · MH · contact PI
Antibodies to NR2 in SLe$339,101
R01 · FY2011 · AR · contact PI
Preventing anti-NMDAR Ab neurotoxicity: Rational therapies for NPSLE$329,513
P01 · FY2011 · AI · contact PI
Monoclonal Antibody Core$176,574
P01 · FY2011 · AI · contact PI
Administrative Core$75,578
P01 · FY2011 · AI · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$2,229,232
P01 · FY2010 · AI · contact PI
Genes and Phenotype (GAP) studies of immunologic and inflammatory pathways$1,222,251
RC2 · FY2010 · AR
Toward a new approach to SLE therapy$373,500
R01 · FY2010 · AR · contact PI
Anti-Microbial Antibodies Induce Neuropsychiatric Syndromes$356,518
R01 · FY2010 · MH · contact PI
Antibodies to NR2 in SLe$353,231
R01 · FY2010 · AR · contact PI
Preventing anti-NMDAR Ab neurotoxicity: Rational therapies for NPSLE$191,180
P01 · FY2010 · AI · contact PI
Monoclonal Antibody Core$102,339
P01 · FY2010 · AI · contact PI
Administrative Core$43,906
P01 · FY2010 · AI · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$2,189,510
P01 · FY2009 · AI · contact PI
Genes and Phenotype (GAP) studies of immunologic and inflammatory pathways$1,268,318
RC2 · FY2009 · AR
Antibodies to NR2 in SLe$356,798
R01 · FY2009 · AR · contact PI
Anti-Microbial Antibodies Induce Neuropsychiatric Syndromes$356,518
R01 · FY2009 · MH · contact PI
Preventing anti-NMDAR Ab neurotoxicity: Rational therapies for NPSLE$187,601
P01 · FY2009 · AI · contact PI
Monoclonal Antibody Core$100,444
P01 · FY2009 · AI · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$100,000
P01 · FY2009 · AI · contact PI
Administrative Core$43,350
P01 · FY2009 · AI · contact PI
Anti-NMDA receptor antibodies in brain dysfunction: lessons from lupus$2,135,361
P01 · FY2008 · AI · contact PI
Antibodies to NR2 in SLe$356,262
R01 · FY2008 · AR · contact PI
Anti-Microbial Antibodies Induce Neuropsychiatric Syndromes$355,760
R01 · FY2008 · MH · contact PI
Preventing anti-NMDAR Ab neurotoxicity: Rational therapies for NPSLE$182,377
P01 · FY2008 · AI · contact PI
Monoclonal Antibody Core$97,516
P01 · FY2008 · AI · contact PI
Administrative Core$42,162
P01 · FY2008 · AI · contact PI
Antibodies to NR2 in SLe$378,692
R01 · FY2007 · AR · contact PI
Anti-Microbial Antibodies Induce Neuropsychiatric Syndromes$355,001
R01 · FY2007 · MH · contact PI
Understanding the SELENA trial: Estrogen in Lupus$352,013
R01 · FY2007 · AI · contact PI
Autoimmunity Centers of Excellence$1
U19 · FY2007 · AI · contact PI
Autoimmunity Centers of Excellence$4,895,579
U19 · FY2006 · AI · contact PI
Studies of Human and Murine SLE$929,766
P01 · FY2006 · AI · contact PI
Understanding the SELENA trial: Estrogen in Lupus$353,738
R01 · FY2006 · AI · contact PI
Antibodies to NR2 in SLE$339,980
R01 · FY2006 · AR · contact PI
Autoimmunity Centers of Excellence$5,000,476
U19 · FY2005 · AI
Studies of Human and Murine SLE$927,371
P01 · FY2005 · AI
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$495,082
R37 · FY2005 · AR
Sex-based Differences in the Immune Response$402,500
R01 · FY2005 · AI
Understanding the SELENA trial: Estrogen in Lupus$362,250
R01 · FY2005 · AI
Antibodies to NR2 in SLE$348,163
R01 · FY2005 · AR
An antigen induced model of SLE$337,303
R01 · FY2005 · AR
An antigen induced model of SLE$24,947
R01 · FY2005 · AR
NR2 GLUT IN SLE$2,344
M01 · FY2005 · RR
Autoimmunity Centers of Excellence$4,795,243
U19 · FY2004 · AI
Studies of Human and Murine SLE$820,492
P01 · FY2004 · AI
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$479,231
R37 · FY2004 · AR
Studies of Human and Murine SLE$421,470
P01 · FY2004 · AI
An antigen induced model of SLE$375,750
R01 · FY2004 · AR
Understanding the SELENA trial: Estrogen in Lupus$362,250
R01 · FY2004 · AI
Antibodies to NR2 in SLE$338,100
R01 · FY2004 · AR
Sex-based Differences in the Immune Response$322,000
R01 · FY2004 · AI
Autoimmunity Centers of Excellence$209,666
U19 · FY2004 · AI
Antibodies to NR2 in SLE$166,110
R01 · FY2004 · AR
Sex-based Differences in the Immune Response$83,500
R01 · FY2004 · AI
Antibodies to NR2 in SLE$41,750
R01 · FY2004 · AR
NR2 GLUT in SLE$19,400
M01 · FY2004 · RR
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$18,863
R37 · FY2004 · AR
SELENA$2,910
M01 · FY2004 · RR
FASEB Research Conference on: Autoimmunity$1
R13 · FY2004 · AI
Autoimmunity Centers of Excellence$2,528,506
U19 · FY2003 · AI
Medical Scientist Training Program$1,555,790
T32 · FY2003 · GM
Studies of Human and Murine SLE$1,347,700
P01 · FY2003 · AI
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$519,238
R37 · FY2003 · AR
Sex-based Differences in the Immune Response$417,500
R01 · FY2003 · AI
Antibodies to NR2 in SLE$392,450
R01 · FY2003 · AR
An antigen induced model of SLE$375,750
R01 · FY2003 · AR
FASEB Research Conference on: Autoimmunity$18,000
R13 · FY2003 · AI
MEDICAL SCIENTIST TRAINING PROGRAM$1,297,231
T32 · FY2002 · GM
Studies of systemic lupus erythematosus$669,441
P01 · FY2002 · AI
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$500,583
R37 · FY2002 · AR
Sex-based Differences in the Immune Response$417,500
R01 · FY2002 · AI
Antibodies to NR2 in SLE$392,450
R01 · FY2002 · AR
An antigen induced model of SLE$375,750
R01 · FY2002 · AR
Instrumentation Grant FACSVantage$267,531
S10 · FY2002 · RR
CORE--FLUORESCENT ACTIVATED CELL SORTER$0
P30 · FY2002 · CA
Core--Flow Cytometry$0
P01 · FY2002 · AI
Peripheral blood B cells in systemic lupus erythematosus$0
P01 · FY2002 · AI
MEDICAL SCIENTIST TRAINING PROGRAM$1,233,088
T32 · FY2001 · GM
MOLECULAR ANALYSIS OF AUTOANTIBODY FORMATION$788,981
P01 · FY2001 · AI
ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS$489,552
R37 · FY2001 · AR
An antigen induced model of SLE$373,654
R01 · FY2001 · AR
ESTROGEN EFFECTS ON B CELL REPERTOIRE SELECTION$247,465
P01 · FY2001 · AI
CORE--FLUORESCENT ACTIVATED CELL SORTER$0
P30 · FY2001 · CA
CORE--FLUORESCENT ACTIVATED CELL SORTER FACILITY$0
P30 · FY2001 · CA